The healthcare technology sector is presently under significant scrutiny from investors, which is justified by the level of innovation occurring within the industry. Numerous companies warrant examination at this time, and Intelligent Bio Solutions Inc. (NASDAQ: INBS) is among them.
Earlier in February 2024, Intelligent Bio Solutions Inc. (NASDAQ: INBS) experienced a notable uptick, with its stock climbing to nearly $7 per share, peaking at $11.70 during intraday trading. However, this surge was followed by a downturn prompted by increased short selling activity. On Tuesday, February 27, 2024, INBS saw a 16.23% increase in its closing price to $4.87 due to short covering, albeit on lower-than-average trading volume. There's speculation circulating that investors may want to consider adding this stock to their BUY LIST, anticipating a potential significant rebound to surpass its recent intraday high of $11.70 in February 2024.
Renowned for its rapid, non-invasive, and intelligent testing solutions, the medical technology company made headlines on February 28th following its announcement of a collaboration with Cliantha Research, a full-service Clinical Research Organization (CRO). This partnership entails participation in a pharmacokinetic (PK) study, forming part of the FDA 510(K) clinical study program at Intelligent Bio Solutions. The PK study, conducted under a regulatory and IRB/EX-approved protocol, aims to recruit up to 40 healthy adults. Ultimately, it will compare opiate levels in fingerprint sweat with those in oral fluid, blood, and urine post-drug administration.
The Intelligent Fingerprint Drug Screening System, developed by Intelligent Bio Solutions, will be utilized to analyze fingerprint sweat specimens. The initiation of the clinical study represents a significant milestone for the company as it progresses along its 510(K) pathway. Harry Simeonidis, President and CEO of Intelligent Bio Solutions, also commented on this advancement. He highlighted the company's satisfaction regarding the collaboration with Cliantha and the upcoming advancement along its 510(K) pathway. He emphasized that Intelligent Bio Solutions had devised a comprehensive plan it aimed to execute and underscored the substantial tasks awaiting the company and its team.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
